Supplementary Figure S1 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma

Abstract

<p>Figure S1: EGFR and PI3K signaling in 5 PDAC cell lines. (A) Densitometric quantitation of Western blotting of pAkt/ total Akt (left panel) and pERK/ total ERK (right panel), with no treatment (NT), or stimulation by EGF, IGF-1, or both growth factors: average  SEM of 3 experiments. (B) Quantitation of Western blot of pEGFR, pIGF1R, pERK and pAkt in response to increasing dose of erlotinib or NVP-AEW541, average of 3 experiments. Drug doses were selected based on relative potency from proliferation assay and investigator brochure. Note that all signals were adjusted to EGF-stimulated control, so for PANC-1 which had a much more highly EGF-stimulated pAkt, the relative fold-change with erlotinib inhibition appeared smaller than for BxPC-3. * P<0.05, ** P<0.01</p>